Brief: Nanobiotix Announces Updated Phase 1 Results Continuing To Support JNJ-1900 (Nbtxr3) Plus Anti-Pd-1 As A Potential New 1L Or 2L+ Option In Anti-Pd-1 Naïve Or Resistant R/M-Hnscc
29/09/2025 23:33
Sept 29 (Reuters) - Nanobiotix SA NANOB.PA: REG-NANOBIOTIX ANNOUNCES UPDATED PHASE 1 RESULTS CONTINUING TO SUPPORT JNJ-1900 (NBTXR3) PLUS ANTI-PD-1 AS A POTENTIAL NEW 1L OR 2L+ OPTION IN ANTI-PD-1 NAÏVE OR RESISTANT R/M-HNSCC Source text: ID:nGNE7mfZdJ Further company coverage: NANOB.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering